These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19553640)

  • 1. Synthetic lethality--a new direction in cancer-drug development.
    Iglehart JD; Silver DP
    N Engl J Med; 2009 Jul; 361(2):189-91. PubMed ID: 19553640
    [No Abstract]   [Full Text] [Related]  

  • 2. [Olaparib in ovarian cancer with BRCA mutation].
    Pujade-Lauraine É; Combe P
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S82-4. PubMed ID: 26118881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PARP inhibitors and breast cancer: update and perspectives].
    Gonçalves A
    Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hereditary ovarian carcinomas: clinico-biological features and treatment].
    Floquet A; Stoeckle E; Croce S; Longy M; Mc Grogan G; Barouk E; Bubien V; Garbay D; Joly E; Guyon F
    Bull Cancer; 2014 Feb; 101(2):167-74. PubMed ID: 24555961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibition in BRCA-mutated breast and ovarian cancers.
    Chan SL; Mok T
    Lancet; 2010 Jul; 376(9737):211-3. PubMed ID: 20656109
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of poly(ADP-ribose) polymerase in BRCA mutation carriers.
    Li S
    N Engl J Med; 2009 Oct; 361(17):1707; author reply 1707-8. PubMed ID: 19846859
    [No Abstract]   [Full Text] [Related]  

  • 7. BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
    Sahin I; Ararat E; Altundag K
    J BUON; 2011; 16(1):184-5. PubMed ID: 21674877
    [No Abstract]   [Full Text] [Related]  

  • 8. Combining carefully selected drug, patient genetics may lead to total tumor death.
    Tuma RS
    J Natl Cancer Inst; 2007 Oct; 99(20):1505-6, 1509. PubMed ID: 17925530
    [No Abstract]   [Full Text] [Related]  

  • 9. PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
    Kruse V; Rottey S; De Backer O; Van Belle S; Cocquyt V; Denys H
    Acta Clin Belg; 2011; 66(1):2-9. PubMed ID: 21485757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.
    Veeck J; Ropero S; Setien F; Gonzalez-Suarez E; Osorio A; Benitez J; Herman JG; Esteller M
    J Clin Oncol; 2010 Oct; 28(29):e563-4; author reply e565-6. PubMed ID: 20679605
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
    Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib effective in four advanced cancers.
    Cancer Discov; 2015 Jan; 5(1):OF3. PubMed ID: 25583815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
    Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
    J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
    Chen Y; Zhang L; Hao Q
    Arch Gynecol Obstet; 2013 Aug; 288(2):367-74. PubMed ID: 23619942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
    Gartner EM; Burger AM; Lorusso PM
    Cancer J; 2010; 16(2):83-90. PubMed ID: 20404603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
    Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resurrected cancer drug faces regulators.
    Ledford H
    Nature; 2014 Jun; 510(7506):454. PubMed ID: 24965630
    [No Abstract]   [Full Text] [Related]  

  • 18. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.
    Domchek SM; Mitchell G; Lindeman GJ; Tung NM; Balmaña J; Isakoff SJ; Schmutzler R; Audeh MW; Loman N; Scott C; Friedlander M; Kaufman B; Garber JE; Tutt A; Robson ME
    J Clin Oncol; 2011 Nov; 29(32):4224-6. PubMed ID: 21931031
    [No Abstract]   [Full Text] [Related]  

  • 19. Treating cancer by targeting a weakness.
    Brody LC
    N Engl J Med; 2005 Sep; 353(9):949-50. PubMed ID: 16135843
    [No Abstract]   [Full Text] [Related]  

  • 20. A snapshot of chemoresistance to PARP inhibitors.
    Chiarugi A
    Trends Pharmacol Sci; 2012 Jan; 33(1):42-8. PubMed ID: 22055391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.